Antibiotic treatment of initial colonization withPseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis

Frederiksen, Birgitte; Koch, Christian; Høiby, Niels

doi:10.1002/(sici)1099-0496(199705)23:5<330::aid-ppul4>3.0.co;2-o

Cited by 451 publications

(334 citation statements)

References 18 publications

Supporting

Mentioning

317

Contrasting

Unclassified

Order By: Relevance

“…Similarly, a placebo controlled doubleblinded, randomized tobramycin inhalation study showed that after onset of P. aeruginosa colonization, the time of conversion to a P. aeruginosa negative respiratory culture was significantly shortened by active treatment, suggesting that early tobramycin inhalation may prevent P. aeruginosa pulmonary infection in CF [148]. In a follow-up study [72], it was demonstrated that aggressive treatment prevented or delayed chronic P. aeruginosa infection in 78% of the CF patients for 3.5 yrs. After introduction of early intensive antibiotic treatment, the probability of still not having developed chronic P. aeruginosa infection 7 yrs after the first isolation of P. aeruginosa was >80% [184].…”

Section: Antibiotic Strategies Against Pseudomonas Aeruginosamentioning

confidence: 97%

“…After introduction of early intensive antibiotic treatment, the probability of still not having developed chronic P. aeruginosa infection 7 yrs after the first isolation of P. aeruginosa was >80% [184]. Furthermore, aggressive treatment maintained or increased pulmonary function during the year after inclusion compared with the control group, in which pulmonary function declined [72].…”

Section: Antibiotic Strategies Against Pseudomonas Aeruginosamentioning

confidence: 99%

“…Due to its chemical nature, a product which upon hydrolysis releases the active drug, a cycle polypeptide, analysis of colistan airway concentrations are impossible to preform and therefore the optimum levels are not known. Efficiency has been shown at doses ranging from 1 million units twice daily [43] to 2 million units three times daily [72]. Colistin has been used with efficiency by the parenteral route in patients with multiresistant P. aeruginosa infection [73,74].…”

Section: Penetration Of Antibiotics Into Respiratory Secretions and Pmentioning

confidence: 99%

“…A multicentre study including 520 CF patients in the USA demonstrated conclusively that chronic intermittent therapy with tobramycin improved lung function, and reduced hospitalization and concomitant intravenous therapy [33]. Aerosolized colistin in combination with oral ciprofloxacin has been shown to significantly postpone chronic P. aeruginosa infection in CF patients [72,146] and to maintain pulmonary function during the year after inclusion compared with the control group, in which pulmonary function declined [72]. Similarly, tobramycin inhalation may prevent P. aeruginosa pulmonary infection in CF [148].…”

Section: Nebulized Antipseudomonal Antibiotic Therapy In Cystic Fibrosismentioning

confidence: 99%

See 3 more Smart Citations

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus

Döring¹,

Conway²,

Heijerman³

et al. 2000

Eur Respir J

558

478

View full text Add to dashboard Cite

Cystic fibrosis (CF) is the most common lethal hereditary disorder with autosomal recessive heredity in caucasians. The majority of CF patients suffer from chronic respiratory infection with the opportunistic bacterial pathogen Pseudomonas aeruginosa. No consensus among clinicians has been reached so far concerning antibiotic treatment against P. aeruginosa in CF patients.Consensus answers to 24 important questions in this context, based on current evidence, are presented, given by a panel of 34 European experts. Questions addressed and answered are: The diagnosis of P. aeruginosa lung colonization in CF; The impact of P. aeruginosa on the clinical state of CF patients; The assessment of P. aeruginosa susceptibility against antibiotics and the importance of these results for the clinician; The use of monotherapy versus combination therapy; The development of microbial resistance; The achievement of optimal airway concentrations; The effects of subinhibitory concentrations of antibiotics on P. aeruginosa; Statements on the pharmacokinetics of antibiotics in CF patients; Recommendations for doses and dosing intervals and length of treatment regimens; and Toxic side effects due to repeated antibiotic therapy was addressed.The expert panel answered further questions on the use of fluoroquinolones in children with CF, on the administration of nebulized antibiotics and whether prevention of P. aeruginosa lung colonization is possible in CF using antibiotic therapy.Problems of antibiotic therapy at home and in the hospital were addressed, a consensus statement on regular maintenance treatment, or treatment on demand, was given and different routes of administration of antibiotics were recommended for different clinical situations.Finally, the factors which determine the choice of the antibiotic, the dosage, and the duration of the treatment in cystic fibrosis patients were addressed and the design of future antibiotic studies in the context of Pseudomonas aeruginosa lung infection in cystic fibrosis patients were recommended. Eur Respir J 2000; 16: 749±767.

show abstract

Section: Antibiotic Strategies Against Pseudomonas Aeruginosamentioning

confidence: 97%

Section: Antibiotic Strategies Against Pseudomonas Aeruginosamentioning

confidence: 99%

Section: Penetration Of Antibiotics Into Respiratory Secretions and Pmentioning

confidence: 99%

Section: Nebulized Antipseudomonal Antibiotic Therapy In Cystic Fibrosismentioning

confidence: 99%

See 2 more Smart Citations

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus

Döring¹,

Conway²,

Heijerman³

et al. 2000

Eur Respir J

558

478

View full text Add to dashboard Cite

show abstract

“…Chronic lower respiratory tract infection is the predominant manifestation of cystic fibrosis (CF). In young CF patients it is important to recognize and treat lung infection as early as possible, since with correct treatment Pseudomonas aeruginosa colonization can be avoided or delayed [1,2]. A culture from the lower airway secretions is necessary to guide antimicrobial therapy.…”

mentioning

confidence: 99%

Sputum induction in young cystic fibrosis patients

Boeck¹,

Alifier²,

Vandeputte³

2000

Eur Respir J

View full text Add to dashboard Cite

A culture from the lower airway secretions is the optimal sample to guide antibiotic therapy in cystic fibrosis (CF) lung disease. The authors therefore examined whether sputum induction is an efficient, safe and acceptable procedure in CF children without spontaneous expectorations.Nineteen patients were studied. Their mean age (range) was 8.6 yrs (4.3±15.2 yrs). Their mean forced expiratory volume in one second (FEV1) was 88% predicted (46± 122%). NaCl solutions from 0.9±6% were inhaled, after baseline lung function tests before and after salbutamol.All patients did produce secretions. Alveolar macrophages were present in 16/19 induced samples. The procedure induced minor but significant bronchoconstriction: the mean change (range) in postsalbutamol FEV1 (% pred) was -7 (-24±16). Percutaneous oxygen saturation remained above 90% in all children. The test had to be discontinued in one child because of cough and wheeze. Acceptability of the procedure evaluated using a visual analogue scale from -7±7 showed a mean value (range) at the final concentration of -1.23 (-6.16±5.88).It is concluded that sputum induction is possible, safe and acceptable in cystic fibrosis children who do not expectorate spontaneously. Chronic lower respiratory tract infection is the predominant manifestation of cystic fibrosis (CF). In young CF patients it is important to recognize and treat lung infection as early as possible, since with correct treatment Pseudomonas aeruginosa colonization can be avoided or delayed [1,2]. A culture from the lower airway secretions is necessary to guide antimicrobial therapy. Sputum cultures are considered a valuable substitute for a lower airway sample obtained by bronchoscopy or thoracotomy, since results from both sites will correspond in over 70% of cases [3].Many young CF patients do not produce sputum. Since oropharyngeal cultures have only a poor positive predictive value [4,5], bronchoalveolar lavage (BAL) remains the standard technique to obtain a lower airway sample in these patients. It is, however, an expensive, time consuming, unpleasant and potentially harmful procedure.Recently, in patients infected with Pneumocystis carinii and Mycobacteria [6±8], sputum induction during hypertonic saline inhalation was proven to provide information comparable to that obtained by bronchoscopy and BAL. Similarly, cytological evaluation of induced sputum is considered helpful in patients with asthma and lung malignancies [9±11]. Sputum induction using hypertonic saline is efficacious in >90% of adult asthmatics [12]. Although the drop in postsalbutamol forced expiratory volume in one second (FEV1) after inhalation was larger in asthmatics than in normals a fall exceeding 20% only occurred in 3/37 patients. Sputum induction using hypertonic saline is also efficacious and safe in adolescent asthmatics [13,14] and isotonic saline sputum induction appears to be safe in children with acute asthma [15]. Although the feasibility of sputum induction has been reported in patients with CF [16], a systemati...

show abstract

Comparative Efficacy and Safety of 4 Randomized Regimens to Treat EarlyPseudomonas aeruginosaInfection in Children With Cystic Fibrosis

Treggiari

Retsch‐Bogart²,

Mayer-Hamblett

et al. 2011

Arch Pediatr Adolesc Med

202

180

View full text Add to dashboard Cite

Antibiotic treatment of initial colonization withPseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis

Cited by 451 publications

References 18 publications

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus

Sputum induction in young cystic fibrosis patients

Comparative Efficacy and Safety of 4 Randomized Regimens to Treat EarlyPseudomonas aeruginosaInfection in Children With Cystic Fibrosis

Contact Info

Product

Resources

About